San Francisco, Jan. 23, 2017 – Recardio named Angela Birchler as Chief Manufacturing Officer and Dave Reed as Vice President of CMC.
Recardio appointed new management positions in manufacturing effective January 2017.
Angela Birchler, Ph.D., was appointed Chief Manufacturing Officer being responsible for product and process development and manufacturing as well as CMC regulatory strategy.
Angela has over 20 years of experience in pharmaceutical development and manufacturing with both biotech and large pharma organizations.
Angela led the development of manufacturing technology for multiple products from preclinical through registration and commercialization. As Vice President of CMC at Phenomix she was responsible for the initial CMC development of dutogliptin as an oral diabetes therapeutic, now exclusively licensed by Recardio with development redirected toward regenerative therapy for acute myocardial infarction and chronic heart failure.
Angela has a Bachelor’s of Science in Chemistry from the Georgia Institute of Technology and a Ph.D. in Organic Synthesis from Emory University.
Dave Reed, Ph.D., was appointed Vice President of CMC being responsible for all aspects of drug development related to the active pharmaceutical ingredient and formulated drug product.
Dave has held various positions of increasing responsibilities in several small biotechnology companies. In his more than 15 years experience, Dave has contributed to several drug development programs ranging from preclinical stage through commercial manufacturing in various roles.
Dave has a Ph.D. in chemistry and is a certified Project Management Professional (PMP).
Angela Birchler added: „I’m pleased to join Recardio to support development of this life saving therapeutic.“
Dr. Roman Schenk, Recardio Executive Chairman commented: “I very much appreciate that Angela and Dave now join our Management Board. Angela already supported us in the past in our successful manufacturing strategy and both will now significantly contribute to the further development of our drug dutogliptin.”
Recardio is a clinical-stage life science company focusing on regenerative therapies for cardiovascular diseases. The company’s lead drug candidate, dutogliptin, is a DPP-IV inhibitor that has demonstrated significant effects in activating SDF-1, a protein that is critical for cardiac regeneration. The company has initiated a Phase 1/2 clinical program, seeking to fully develop the therapeutic platform as a regenerative medication for patients with various cardiovascular diseases including acute myocardial infarction and chronic heart failure, with the potential of improving heart function, quality of life and survival. For more information, visit: http://www.recardio.eu/